In the first three articles of this series, we looked at AI where people can see it: reading scans and drafting treatment plans, tutoring students and simulating patients, and even helping design the next generation of medicines. But some of the most profound changes are happening out of sight, in the operating system of the …
One of the latest health crazes to slip in alongside “peptides” (see our previous series), is the idea that powerful medicines can be repurposed as lifestyle tweaks by “microdosing”: a tiny dose of a diabetes drug to “optimize” metabolism, a fraction of a psychedelic to sharpen focus, or a whisper of a stimulant to fuel …
Continue reading “Beyond the Hype: Why Microdosing Falls Short of Science”
The first article of this series argued that the peptide boom is not just a fringe fad but a parallel ecosystem, built by people who feel conventional medicine is too slow, too narrow, or too inaccessible for the goals they care about. In our second article, we asked how far bodily autonomy should extend when …
Continue reading “The Peptide Paradox (3): When the System Has No Middle Ground”
In the first article of this series we explored how collapsing trust in traditional evidence-based systems is fueling the recent boom in the unregulated peptide market. But this gray‑market peptide trend reveals more than a pushback against entrenched regulatory mechanisms. It exposes a deeper ethical divide in modern medicine: a clash between medical paternalism, where doctors …
The gray‑market peptide boom is no longer a fringe curiosity. It has become a growing parallel ecosystem for people who feel conventional medicine is too slow, too restrictive, too expensive, and often not designed for the kinds of outcomes they care about. In this three‑part series we examine that ecosystem: how mistrust of institutions is …
Continue reading “The Peptide Paradox (1): When Institutional Distrust Drives Alternative Science”